Universal vaccines: shifting to one for many.
Identifieur interne : 001270 ( PubMed/Curation ); précédent : 001269; suivant : 001271Universal vaccines: shifting to one for many.
Auteurs : Antonio Cassone [Italie] ; Rino RappuoliSource :
- mBio [ 2150-7511 ] ; 2010.
Abstract
Human vaccines, with their exquisite antigenic specificity, have greatly helped to eliminate or dramatically abate the incidence of a number of historical and current plagues, from smallpox to bacterial meningitis. Nonetheless, as new infectious agents emerge and the number of vaccine-preventable diseases increases, the practice and benefits of single-pathogen- or disease-targeted vaccination may be put at risk by constraints of timely production, formulation complexity, and regulatory hurdles. During the last influenza pandemic, extraordinary efforts by vaccine producers and health authorities have had little or no influence on disease prevention or mitigation. Recent research demonstrating the possibility of protecting against all influenza A virus types or even phylogenetically distant pathogens with vaccines based on highly conserved peptide or saccharide sequences is changing our paradigm. "Universal vaccine" strategies could be particularly advantageous to address protection from antibiotic-resistant bacteria and fungi for which no vaccine is currently available.
DOI: 10.1128/mBio.00042-10
PubMed: 20689748
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001270
Links to Exploration step
pubmed:20689748Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Universal vaccines: shifting to one for many.</title><author><name sortKey="Cassone, Antonio" sort="Cassone, Antonio" uniqKey="Cassone A" first="Antonio" last="Cassone">Antonio Cassone</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious, Parasitic, and Immunomediated Diseases, Istituto Superiore di Sanita`, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Infectious, Parasitic, and Immunomediated Diseases, Istituto Superiore di Sanita`, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Rappuoli, Rino" sort="Rappuoli, Rino" uniqKey="Rappuoli R" first="Rino" last="Rappuoli">Rino Rappuoli</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20689748</idno><idno type="pmid">20689748</idno><idno type="doi">10.1128/mBio.00042-10</idno><idno type="wicri:Area/PubMed/Corpus">001270</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001270</idno><idno type="wicri:Area/PubMed/Curation">001270</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001270</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Universal vaccines: shifting to one for many.</title><author><name sortKey="Cassone, Antonio" sort="Cassone, Antonio" uniqKey="Cassone A" first="Antonio" last="Cassone">Antonio Cassone</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious, Parasitic, and Immunomediated Diseases, Istituto Superiore di Sanita`, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Infectious, Parasitic, and Immunomediated Diseases, Istituto Superiore di Sanita`, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Rappuoli, Rino" sort="Rappuoli, Rino" uniqKey="Rappuoli R" first="Rino" last="Rappuoli">Rino Rappuoli</name></author></analytic><series><title level="j">mBio</title><idno type="eISSN">2150-7511</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human vaccines, with their exquisite antigenic specificity, have greatly helped to eliminate or dramatically abate the incidence of a number of historical and current plagues, from smallpox to bacterial meningitis. Nonetheless, as new infectious agents emerge and the number of vaccine-preventable diseases increases, the practice and benefits of single-pathogen- or disease-targeted vaccination may be put at risk by constraints of timely production, formulation complexity, and regulatory hurdles. During the last influenza pandemic, extraordinary efforts by vaccine producers and health authorities have had little or no influence on disease prevention or mitigation. Recent research demonstrating the possibility of protecting against all influenza A virus types or even phylogenetically distant pathogens with vaccines based on highly conserved peptide or saccharide sequences is changing our paradigm. "Universal vaccine" strategies could be particularly advantageous to address protection from antibiotic-resistant bacteria and fungi for which no vaccine is currently available.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">20689748</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2150-7511</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>mBio</Title><ISOAbbreviation>mBio</ISOAbbreviation></Journal><ArticleTitle>Universal vaccines: shifting to one for many.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1128/mBio.00042-10</ELocationID><ELocationID EIdType="pii" ValidYN="Y">e00042-10</ELocationID><Abstract><AbstractText>Human vaccines, with their exquisite antigenic specificity, have greatly helped to eliminate or dramatically abate the incidence of a number of historical and current plagues, from smallpox to bacterial meningitis. Nonetheless, as new infectious agents emerge and the number of vaccine-preventable diseases increases, the practice and benefits of single-pathogen- or disease-targeted vaccination may be put at risk by constraints of timely production, formulation complexity, and regulatory hurdles. During the last influenza pandemic, extraordinary efforts by vaccine producers and health authorities have had little or no influence on disease prevention or mitigation. Recent research demonstrating the possibility of protecting against all influenza A virus types or even phylogenetically distant pathogens with vaccines based on highly conserved peptide or saccharide sequences is changing our paradigm. "Universal vaccine" strategies could be particularly advantageous to address protection from antibiotic-resistant bacteria and fungi for which no vaccine is currently available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cassone</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious, Parasitic, and Immunomediated Diseases, Istituto Superiore di Sanita`, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rappuoli</LastName><ForeName>Rino</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>mBio</MedlineTA><NlmUniqueID>101519231</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20689748</ArticleId><ArticleId IdType="doi">10.1128/mBio.00042-10</ArticleId><ArticleId IdType="pmc">PMC2912660</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2008 Feb;8(2):114-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18222162</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosecur Bioterror. 2009 Sep;7(3):265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19656012</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2009 Nov;15(11):1251-2</Citation><ArticleIdList><ArticleId IdType="pubmed">19893556</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug News Perspect. 2009 Mar;22(2):80-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19330167</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1994 Mar 15;152(6):3175-82</Citation><ArticleIdList><ArticleId IdType="pubmed">8144911</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2007;2(10):e984</Citation><ArticleIdList><ArticleId IdType="pubmed">17912361</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2009 Dec;5(12):e1000703</Citation><ArticleIdList><ArticleId IdType="pubmed">20041174</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2010 Mar;78(3):1276-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20038538</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbes Infect. 2010 Apr;12(4):280-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20079871</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Feb 1;201(3):473-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20039802</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2006 Dec;5(6):859-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17184223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Vet Mycol. 1991;29(4):235-42</Citation><ArticleIdList><ArticleId IdType="pubmed">1941431</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2010 May 18;1(1):null</Citation><ArticleIdList><ArticleId IdType="pubmed">20689752</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Genet. 2009 Oct;5(10):e1000612</Citation><ArticleIdList><ArticleId IdType="pubmed">19855822</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Anti Infect Ther. 2010 Feb;8(2):117-25</Citation><ArticleIdList><ArticleId IdType="pubmed">20109042</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Dis Clin North Am. 2009 Dec;23(4):847-64, vii-viii</Citation><ArticleIdList><ArticleId IdType="pubmed">19909887</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin. 2007 Nov-Dec;3(6):290-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17712231</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2009 Dec;5(12):e1000695</Citation><ArticleIdList><ArticleId IdType="pubmed">20019801</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2007 Nov;75(11):5085-94</Citation><ArticleIdList><ArticleId IdType="pubmed">17606600</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2010 Feb;78(2):764-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19948836</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Jun 2;27(27):3662-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19464548</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2007 Nov;75(11):5074-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17709417</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2005 Sep 5;202(5):597-606</Citation><ArticleIdList><ArticleId IdType="pubmed">16147975</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Oct 23;27(45):6280-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19840661</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Jan 10;26(2):201-14</Citation><ArticleIdList><ArticleId IdType="pubmed">18063235</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001270 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001270 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:20689748
|texte= Universal vaccines: shifting to one for many.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:20689748" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |